Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 7/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449840 | 0.91 | BACE1 (0.42) | BACE1CTSDGRM5MAPKAPK2 | |
| SCHEMBL449668 | 0.85 | PGR (0.39) | BACE1PGRKDM5BMAPKAPK2 | |
| SCHEMBL446794 | 0.83 | BACE1 (0.39) | BACE1GRM5PGR | |
| SCHEMBL429255 | 0.78 | BACE1 (0.57) | BACE1CTSD | |
| SCHEMBL445570 | 0.77 | BACE1 (0.37) | BACE1GRM5PGRMAPKAPK2 | |
| SCHEMBL427954 | 0.73 | BACE1 (0.53) | BACE1CTSD | |
| SCHEMBL2552657 | 0.73 | PGR (0.39) | BACE1GRM5PGRKDM5BMAPKAPK2 | |
| SCHEMBL448377 | 0.72 | PGR (0.45) | GRM5PGRKDM5BMAPKAPK2 | |
| SCHEMBL2554654 | 0.71 | PGR (0.38) | BACE1GRM5PGRKDM5B | |
| SCHEMBL429224 | 0.66 | BACE1 (0.66) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885CTSD 427/4885GRM5 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.